We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to ...

With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.

Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate ...

2 Variant Available Pfizer and Moderna mRNA vaccines are updated to better match currently circulating COVID strains, while the Novavax adjuvant will target the JN.1 variant — a predecessor of ...

innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. Hear more from InvestingChannel by signing up for The Spill. The Fly will report on a ...

Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its ...

In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) crossed above their 200 day moving average of $10.66, changing hands as high as $11.55 per share. Novavax, Inc. shares are currently ...

The company is also developing proprietary immune stimulating saponin-based adjuvants. It operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech ...

At 12-year follow-up, C9741 confirmed the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer. SET2,3 identified patients with ER+ breast cancer who ...